Skip to main content

Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression.

Publication ,  Conference
Stone, S; Cooperberg, MR; Flake, DD; Davis, JW; Moul, JW; Tward, JD; Brawer, MK
Published in: Journal of Clinical Oncology
May 20, 2017

e16566 Background: A CCP score has been developed and validated to provide prognostic information in prostate cancer. To date, our studies have exclusively used qRT-PCR to measure CCP gene expression, which is generally considered the ‘gold-standard’ for measuring RNA expression levels. However, qRT-PCR allows for the interrogation of a relatively small number of genes. Because prostate cancer biopsies provide very limited tissue, there is interest in evaluating RNA expression platforms that could simultaneously integrate CCP genes and other less characterized targets that might be clinically useful. Here we evaluate the ability of microarrays to measure CCP gene expression. Methods: CCP scores for 1636 radical prostatectomy samples submitted for commercial testing were generated from the mean expression of 31 CCP genes and 15 housekeeping genes as determined by qRT-PCR. CCP scores were also generated from several publically available Affymetrix microarray expression data sets (Nakagawa et al. 2008, Karnes et al. 2013, Klein et al. 2014, Boormans et al. 2013, Taylor et al. 2013) by averaging the intensities (RMA processed, base 2 log scale) of the 31 CCP genes. Expression data were evaluated by comparing CCP score range and pairwise correlations between CCP genes. Results: The average pair-wise correlation in the commercial cohort using qRT-PCR was 0.67. The pair-wise correlations in the microarray studies were significantly lower, ranging from 0.17 (Klein) to 0.58 (Boormans). Importantly, the data in Boormans et al. was generated from frozen tissue. The CCP score in our commercial cohort ranged from -2 to 3 (base 2 log scale) with a standard deviation (SD) of 0.79. In contrast, the CCP score range in microarray studies was highly truncated with SDs ranging from 0.12 (Nakagawa) to 0.46 (Boormans). Conclusions: Expression of CCP genes as determined by microarrays correlates weakly with expression measured by qRT-PCR, with reduction in normally observed pairwise correlations among CCP genes and the range of CCP scores. This is especially true if the RNA is derived from fixed tissue. As a result, microarray generated CCP scores cannot be assumed to be a valid surrogate for qRT-PCR generated scores for prediction of patient outcome.

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2017

Volume

35

Issue

15_suppl

Start / End Page

e16566 / e16566

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stone, S., Cooperberg, M. R., Flake, D. D., Davis, J. W., Moul, J. W., Tward, J. D., & Brawer, M. K. (2017). Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression. In Journal of Clinical Oncology (Vol. 35, pp. e16566–e16566). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2017.35.15_suppl.e16566
Stone, Steven, Matthew R. Cooperberg, Darl D. Flake, John W. Davis, Judd W. Moul, Jonathan David Tward, and Michael K. Brawer. “Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression.” In Journal of Clinical Oncology, 35:e16566–e16566. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.e16566.
Stone S, Cooperberg MR, Flake DD, Davis JW, Moul JW, Tward JD, et al. Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017. p. e16566–e16566.
Stone, Steven, et al. “Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression.Journal of Clinical Oncology, vol. 35, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2017, pp. e16566–e16566. Crossref, doi:10.1200/jco.2017.35.15_suppl.e16566.
Stone S, Cooperberg MR, Flake DD, Davis JW, Moul JW, Tward JD, Brawer MK. Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017. p. e16566–e16566.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2017

Volume

35

Issue

15_suppl

Start / End Page

e16566 / e16566

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis